News & Events
10.09.24
Anavo Therapeutics Appoints Dr. Edward Holson as Chief Scientific Officer and President US
In October 2024, Anavo Therapeutics announced the appointment of Edward Holson, Ph.D., as Chief Scientific Officer.
9.21.23
Anavo Therapeutics Strengthens Management Team
In September 2023, Anavo Therapeutics welcomed industry veteran Shaun McNulty as Chief Scientific Officer and R&D expert Anna Quattropani as SVP Chemistry & Non-Clinical Development.
5.2.23
Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic
In May 2023, Anavo Therapeutics announced an extended seed round to EUR 28 million with new investor MRL Ventures Fund and all existing investors participating - M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
12.9.21
Anavo Therapeutics Announces the Appointment of Charles McDermott as Chairman of the Board
In December 2021, Anavo Therapeutics announced the appointment of Charles McDermott as Chairman of the Board of Directors. Mr. McDermott currently serves as the Chairman, CEO and President of Primmune Therapeutics.
8.16.21
Anavo Therapeutics to Establish R&D Hub in World-Leading Cancer Research Cluster
In August 2021, Anavo Therapeutics announced that the company will establish its R&D center as one of the first tenants at the newly established BioLabs life-sciences start-up incubator in Heidelberg, Germany.
6.24.21
Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology
In June 2021, Anavo Therapeutics announced three key appointments to its Scientific Advisory Board in the persons of Karl-Heinz Altmann, Andrew Mortlock, and Gregg Siegal.
4.22.21
Anavo Therapeutics Launches with EUR20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
In April 2021, Anavo Therapeutics, debuted with a EUR20 million (approx. $24 million) seed financing. The round was led by M Ventures and co-led by INKEF Capital with additional investments by Taiho Ventures and Bioqube Ventures.